[The dynamics of the immunological indices during the treatment of recurrent erysipelas with the new immunostimulant bemitil].

Abstract

Bemitil, administered orally in a dose of 0.25-0.5 g a day for 5-7 days at the acute period of the relapse of erysipelas as an immunostimulant, enhanced the effectiveness of the basic therapy including antibiotics, anti-inflammatory and antiallergic drugs, vitamins, plasma-substituting fluids and saline solutions, as well as ultraviolet irradiation of the focus of lesion. Bemitil therapy was associated with an increase in the number of T-lymphocytes, normalization of the balance between the peripheral lymphocyte preparations, an increase of blood serum levels of IgA and IgM.

• Authors: L I Ratnikova
• Journal: Zhurnal mikrobiologii, epidemiologii i immunobiologii (Zh Mikrobiol Epidemiol Immunobiol) Issue 9 Pg. 56-8 (Sep 1991) ISSN: 0372-9311 [Print] Russia (Federation)
• Vernacular Title: Dinamika nekotorykh immunologicheskikh pokazateleĭ pri lechenii retsidiviruiushcheĭ rozhi novym immunostimuliatorom bemitilom.
• PMID: 1759524 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Benzimidazoles
• bemethyl

Topics

• Adjuvants, Immunologic (therapeutic use)
• Antibody Formation (drug effects, immunology)
• Benzimidazoles (therapeutic use)
• Combined Modality Therapy
• Drug Evaluation
• Erysipelas (drug therapy, immunology)
• Humans
• Immunity, Cellular (drug effects, immunology)
• Length of Stay
• Recurrence
• Time Factors